Development

Sensorion pushes AAV gene therapy targeting connexin 26 mutations toward clinic for most common genetic deafness

Sensorion, a French clinical-stage biotechnology company, announced on March 23, 2026, that it is advancing SENS-601 (GJB2-GT), an AAV-based gene therapy...

Sensorion Advances SENS-601 Toward First-in-Human Gene Therapy for GJB2-Related Deafness

Sensorion, a French clinical-stage biotechnology company, announced on March 23, 2026, that it is advancing SENS-601 (GJB2-GT), an AAV-based gene therapy targeting mutations in the GJB2 gene, toward first-in-human clinical development. The GJB2 gene encodes connexin 26, a gap junction protein that maintains the ionic balance required for sound transduction in the inner ear. GJB2 mutations account for approximately 50% of autosomal recessive non-syndromic hearing loss, making this the single largest genetic cause of congenital deafness. Sensorion is targeting a Clinical Trial Application submission in the first half of 2026 in Europe and an IND submission to the FDA by year-end 2026. Developed in collaboration with the Institut Pasteur, SENS-601 preclinical safety, biodistribution, and efficacy data will be presented at the ASGCT annual meeting in May 2026. No trial registry listing, enrolment target, dosing schedule, or endpoint structure has been disclosed for the planned first-in-human study. (Source)

The announcement accompanied updated Audiogene trial results for Sensorion SENS-501, the company's gene therapy for otoferlin-mediated deafness (DFNB9), now in a Phase 1/2 OTOF gene therapy clinical trial. Six-month follow-up data from Cohort 2 showed sustained directional improvements in pure-tone audiometry in two of three patients treated at the higher dose, consistent with a dose-response relationship across cohorts. Across all six patients dosed in the escalation phase, no serious adverse events were reported. Sensorion is considering a third dose level and will consult regulatory authorities. The Audiogene trial enrolls children aged 6 to 31 months, with safety as the primary endpoint in the dose-escalation portion and auditory brainstem response as the primary efficacy endpoint in the expansion cohort.

Research Context

The rationale for pursuing GJB2 as a gene therapy target rests on the gene's central role in cochlear physiology and the scale of the affected population. Connexin 26 forms gap junctions between supporting cells of the cochlea, enabling potassium recycling essential for hair cell depolarization and auditory signal transduction. Loss-of-function mutations abolish this process, causing severe-to-profound hearing loss from birth. Research catalogued on AllSci confirms the high prevalence of GJB2 mutations among hearing loss cohorts and their association with cochlear implant candidacy and performance (Prevalence of Connexin 26 Mutations in Adult Cochlear Implant Candidates; Association of GJB2 Gene Mutation With Cochlear Implant Performance). Clinical experience from Sensorion's Audiogene trial for SENS-501—which has validated the company's surgical delivery platform, intra-cochlear administration, and dose-escalation framework—directly informs the SENS-601 program, providing procedural and safety data transferable to a second monogenic target.

The AllSci BriefSystematic R&D and deal news. Daily.

No approved pharmacological or gene therapy exists for GJB2-related hearing loss. The current standard of care consists of cochlear implants, hearing aids, and speech therapy. Cochlear implants bypass damaged sensory cells to stimulate the auditory nerve, but they provide an artificial representation of sound, with limitations in noisy environments, music perception, and sound localization. They also require lifelong device maintenance and do not address the underlying genetic defect. Studies indexed on AllSci document variable outcomes following cochlear implantation in children with GJB2 mutations and congenital non-syndromic hearing loss (Cochlear Implantation for Children With GJB2-Related Deafness; Auditory Outcome After Cochlear Implantation). No novel drugs or gene therapies have been approved for this indication in the past five years.

The competitive landscape in gene therapy for hearing loss is active but stratified by target gene. The most advanced programs target the OTOF gene rather than GJB2. Regeneron's DB-OTO, acquired from Decibel Therapeutics, is in a Phase 1/2 trial (CHORD) and has announced plans for FDA filing after reporting hearing improvement in 11 of 12 children. Eli Lilly's AK-OTOF, obtained through its Akouos acquisition, is also in Phase 1/2. Multiple Chinese academic programs, including those at Fudan University and involving HuidaGene Therapeutics, have reported clinical results for OTOF gene therapy. Additional OTOF-targeting trials are listed on AllSci, including programs from Otovia Therapeutics (OTOV101N+OTOV101C) and the Eye & ENT Hospital of Fudan University (RRG-003). For GJB2 specifically, however, no other sponsor has an interventional clinical trial listed. Sensorion's own observational study characterizing early-onset presbycusis in GJB2 mutation carriers is recruiting (AllSci listing), but SENS-601 appears positioned to be the first interventional gene therapy to enter human testing for this target. The divergence in the field is clear: while OTOF programs compete on clinical maturity, GJB2 remains an open lane addressing a far larger patient population, with the technical challenge of achieving connexin 26 expression in cochlear supporting cells still unresolved in a clinical setting.


Spot something wrong? Report an issue with this article